Video: Who Am I?| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Search results for: rituximab

The Ins & Outs of ILD: The Management & Treatment of ILD in Patients with Rheumatic Disease

  |  

Melissa Griffith, MD, discussed the diagnosis and treatment of interstitial lung disease (ILD) in patients with rheumatic diseases, including connective tissue disease and more.

A positron emission tomography (PET) scan shows a 3 cm, hypermetabolic mass adjacent to the stomach.

Case Report: Elevated Inflammatory Markers & a Hypermetabolic Mass

Lisa L. Korn, MD, PhD, Mina L. Xu, MD, & Cristina Brunet, MD  |  

Consulting rheumatologists often assess patients with atypical clinical presentations for the possibility of an underlying rheumatic disease. Inflammatory syndromes that are not clearly rheumatic in nature can be particularly challenging to diagnose. Here, we share the case of a young woman with a long-standing undiagnosed illness and highly elevated inflammatory markers, and describe the evaluation…

Case Report: GPA Presenting as Neuropathy

Ann George, MD, Azin Azarfar, MD, Shazia Bég, MD, & Maria Farooq, MD  |  

Granulomatosis with polyangiitis (GPA), is a type of anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV) that affects small- to medium-sized vessels.1 It can occur equally in both men and women, with a reported mean age at onset of 55 years.2 The classical presentation of GPA includes upper respiratory tract (i.e., chronic sinusitis, serous otitis and…

Alpha Tauri 3D Graphics / shutterstock.com

Rheumatic Complications from Immune Checkpoint Inhibitors

Nilasha Ghosh, MD, MS, & Anne R. Bass, MD  |  

Immune checkpoint inhibitors (ICIs), such as anti-programmed cell-death 1/programmed death-ligand 1 (anti-PD-1/PD-L1) or anti-CTL-associated protein (anti-CTLA-4), have dramatically changed the treatment of advanced cancers over the past decade. ICIs block T cell inhibition, thus increasing the anti-tumor immune response. ICIs are used not only for metastatic cancer, but also as adjuvant treatment for some stage…

Therapeutics for COVID-19: An update from ACR Convergence 2021

  |  

ACR CONVERGENCE 2021—Rheumatology patients who test positive for COVID-19 would benefit from early use of monoclonal antibodies, said Luis Ostrosky-Zeichner, MD, chief of the Division of Infectious Diseases, McGovern Medical School, University of Texas Health Science Center (UTHealth), Houston, in a session about effective treatment options for COVID-19. Acknowledging that the SARS-CoV-2 virus has already…

Updates on JAK Inhibitor Safety, COVID-19 Vaccination in Immunosuppressed Patients & More

Jeffrey Curtis, MD, MS, MPH  |  

ACR CONVERGENCE 2021—The ACR Convergence 2021 meeting reflected the continued advancement of science and practical research in the field of rheumatoid arthritis (RA). Among the most important topics this year in RA was the evolution of the risk-benefit profile of Janus kinase (JAK) inhibitors, for which new safety data emerged in a series of related…

The State of Clinical Science for Pediatric Rheumatology in 2021

Elizabeth Sloan, MD  |  

ACR Convergence 2021—The Pediatric Rheumatology Year in Review began with a fascinating talk by Mara Becker, MD, MSCE, a professor of Pediatrics and vice chair of faculty at Duke University School of Medicine, Durham, N.C. Dr. Becker began by describing her search strategy to select high-yield clinical science publications in pediatric rheumatology from the past…